EQS-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Annual Results/Forecast DGAP-Adhoc: Limes Schlosskliniken AG: Preliminary group result 2023 (unaudited) / forecast 2024
Cologne, February, 06, 2024: The LIMES Group continued to develop dynamically in 2023. The new location in Liechtenstein has been integrated and is performing significantly better than planned. Patient occupancy was higher at all locations in the second half of the year. After higher costs had to be covered in the first half of 2023 due to inflation, these were largely compensated by delayed price adjustments in the second half of the year. For the current year 2024, we expect sales revenue of around EUR 44 million excluding new acquisitions and gross earnings (EBITDA) of EUR 9.7 million including the start-up losses of the new Abtsee site near Salzburg. Kurzprofil: Die LIMES Schlosskliniken Gruppe betreibt hochwertige Privatkliniken für Stressfolgeerkrankung, Mentale und Seelische Störung, wie z. B. Despressionen, Affektive Störungen und akute Burnout Zustände. Das Angebot richtet sich an Privatpatienten, Beihilfeberechtigte und Selbstzahler. Die LIMES Schlosskliniken Gruppe stehen für den besonderen Ansatz einer beziehungsorientierten Medizin in der Behandlung von Menschen mit seelischen Erkrankungen. Dabei wird den Patienten, neben medizinischer Spitzenqualität, eine einzigartige, geschützte und heilsame Umgebung geboten, in der sie ganzheitlich genesen können. Weitere Informationen sind unter www.limes-schlosskliniken.de abrufbar. Ihr Ansprechpartner bei Rückfragen: End of Inside Information
06-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Limes Schlosskliniken AG |
Kaiser-Wilhelm-Ring 26 | |
50672 Köln | |
Germany | |
ISIN: | DE000A0JDBC7 |
WKN: | A0JDBC |
Listed: | Regulated Unofficial Market in Dusseldorf |
EQS News ID: | 1831535 |
End of Announcement | EQS News Service |
|
1831535 06-Feb-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.